Novo Nordisk vs. Eli Lilly: The $40 Billion GLP-1 Showdown Shaking Pharma
Novo Nordisk and Eli Lilly are locked in a fierce battle for GLP-1 supremacy, but is Novo Nordisk a bargain or a trap? As both giants vie for dominance, investors must weigh the risks and rewards.






